Abstract: A novel fused pyrimidine based sulfonamide derivative represented by Formula I, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient are disclosed. The novel fused pyrimidine based sulfonamide derivative can effectively suppress the growth of cancer cells and resistance to drugs, which are induced by mutations in the tyrosine kinase domain of epidermal growth factor receptors, or the growth of cancer cells having such resistance.

Abstract: The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient.

Abstract: The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient.

Abstract: Disclosed is a method for processing a failure occurring in a network device. The method for processing the failure, performed in a network device connected to at least one controller, comprises the steps of: predicting the failure of the network device; and when the failure of the network device is predicted, notifying at least one controller that the network device will be down. Accordingly, by defining a processing mechanism for each type of router failure, all controllers concerned can quickly grasp the failure information of the router.

Abstract: A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient.

Abstract: A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Abstract: A battery includes a first electrode terminal of a first shape, a second electrode terminal of a second shape, a third electrode terminal of a third shape, and a fourth electrode terminal of a fourth shape. The first and third electrode terminals have a first polarity, and the second and fourth electrode terminals have a second polarity opposite to the first polarity. The first shape is complementary to the second shape, and the third shape is complementary to the fourth shape. The first and second electrode terminals may be on opposing sides of the battery, and the third and fourth electrode terminals may be on a same side of the battery. The first and second electrode terminals may establish series connections of the battery, and the third and fourth electrode terminals may establish parallel connections of the battery.

Abstract: A portable electronic apparatus includes a terminal, a grip portion and a controller. A first battery is provided inside the terminal. The grip portion is positioned outside of the terminal and includes a second battery unit electrically connected to the terminal. The controller controls the second battery unit to supply power to the terminal before power of the first battery unit is supplied to the terminal. Accordingly, the controller first supplies the power of the second battery unit to the terminal rather than the power of the first battery unit.

Abstract: There are provided a wireless communication terminal and a method for supplying power thereof. The wireless communication terminal includes a main battery, an auxiliary battery and a controller. The main battery is attachably/detachably coupled to the terminal to supply power to the terminal. The auxiliary battery is built in the terminal. The controller supplies power to the terminal, using the auxiliary battery, when the main battery is separated from the terminal or when the main battery is discharged. In the wireless communication terminal, the main battery is a high-power and high-capacity battery, and the auxiliary battery is a low-power and low-capacity battery.

Abstract: An electronic device includes an electronic device main body, a battery pack receptacle in the electronic device main body, and at least one variable member at an inner side of the battery pack receptacle, the variable member being movable within the space of the battery pack receptacle.

Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.